Tight Junction Protein Signaling and Cancer Biology

Cells. 2023 Jan 6;12(2):243. doi: 10.3390/cells12020243.

Abstract

Tight junctions (TJs) are intercellular protein complexes that preserve tissue homeostasis and integrity through the control of paracellular permeability and cell polarity. Recent findings have revealed the functional role of TJ proteins outside TJs and beyond their classical cellular functions as selective gatekeepers. This is illustrated by the dysregulation in TJ protein expression levels in response to external and intracellular stimuli, notably during tumorigenesis. A large body of knowledge has uncovered the well-established functional role of TJ proteins in cancer pathogenesis. Mechanistically, TJ proteins act as bidirectional signaling hubs that connect the extracellular compartment to the intracellular compartment. By modulating key signaling pathways, TJ proteins are crucial players in the regulation of cell proliferation, migration, and differentiation, all of which being essential cancer hallmarks crucial for tumor growth and metastasis. TJ proteins also promote the acquisition of stem cell phenotypes in cancer cells. These findings highlight their contribution to carcinogenesis and therapeutic resistance. Moreover, recent preclinical and clinical studies have used TJ proteins as therapeutic targets or prognostic markers. This review summarizes the functional role of TJ proteins in cancer biology and their impact for novel strategies to prevent and treat cancer.

Keywords: carcinogenesis; signaling pathways; therapeutic targets; tight junctions.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biology
  • Cell Differentiation
  • Neoplasms* / metabolism
  • Signal Transduction
  • Tight Junction Proteins* / metabolism
  • Tight Junctions / metabolism

Substances

  • Tight Junction Proteins

Grants and funding

European Research Council Grant ERC-AdG-2014 HEPCIR (T.F.B.), European Research Council Grant ERC-AdG-2020 FIBCAN #101021417 (T.F.B.), European Research Council Grant ERC-PoC-2016 PRELICAN #7555460 (T.F.B.), European Research Council Grant ERC-PoC-2018 HEPCAN #862551 (T.F.B.), ARC Grant TheraHCC2.0 IHUARC IHU201301187 (T.F.B.), ANRS Grant ECTZ103701 (T.F.B.), SATT Conectus, University of Strasbourg (CANCLAU) (T.F.B.), French National Research Agency LABEX ANR-10-LABX-0028_HEPSYS (T.F.B.), RHU Deliver ANR-21-RHUS-0001 (T.F.B), BX002086 (VA merit) (P.D.), CA250383 (NIH/NCI) (P.D.) and Berta-Ottenstein Programme, University Freiburg (N.R.). This work of the Interdisciplinary Thematic Institute IMCBio, as part of the ITI 2021-2028 program of the University of Strasbourg, CNRS and Inserm, was supported by IdEx Unistra (ANR-10-IDEX-0002), and by the SFRI-STRAT’US project (ANR 20-SFRI-0012) and EUR IMCBio (ANR-17-EURE-0023), under the framework of the French Investments for the Future Program. The authors’ work is supported by French state funds managed by the ANR within the France 2030 program (ANR-21-RHUS-0001).